CNTN
Canton Strategic Holdings, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Canton Strategic Holdings, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
No changes.
No changes.
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for the treatment resistant cancers. The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-888, a dual Quatramer loaded IMCD inducer coupled with its anthracycline analogue for solid tumors; HSB-510, a targeted bifunctional inhibitory compound in Quatramer with single digit nanomolar; IC50 against PI3K-delta and HDAC6, which is also known to downregulate; c-myc, a cancer drug target; and HSB-114, an immunotherapeutic agent, which uses its Quatramer technology to deliver tumor necrosis factor-alpha gene into cancer cells. The company was incorporated in 2019 and is based in Bridgewater, New Jersey.
Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for the treatment resistant cancers. The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-888, a dual Quatramer loaded IMCD inducer coupled with its anthracycline analogue for solid tumors; HSB-510, a targeted bifunctional inhibitory compound in Quatramer with single digit nanomolar; IC50 against PI3K-delta and HDAC6, which is also known to downregulate; c-myc, a cancer drug target; and HSB-114, an immunotherapeutic agent, which uses its Quatramer technology to deliver tumor necrosis factor-alpha gene into cancer cells. The company was incorporated in 2019 and is based in Bridgewater, New Jersey.
No thesis.
Annual filing, covered
10-K parsed · Mar 31 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Mar 31 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Same SIC code · 6
Same SEC industry code: American Express Co, Coinbase Global, Inc., Synchrony Financial and 3 more; no measured co-movers for Canton Strategic Holdings, Inc..
Same SIC code · 6
Same SEC industry code: American Express Co, Coinbase Global, Inc., Synchrony Financial and 3 more; no measured co-movers for Canton Strategic Holdings, Inc..
Largest filed tie
0
filed ties
Canton Strategic Holdings, Inc.
1.94
−0.10 · −4.76%
post 1.98 +1.91%
Expected move
No implied move.
| Manager | Value | % base | |
|---|---|---|---|
| ARK | $10.3M | 17.84% | −1.02% |
| BlackRockindex-like | $10.3M | 17.77% | +375.73% |
| Vanguardindex-like | $8.5M | 14.72% | +566.87% |
| DRW Securities | $4.9M | 8.41% | new |
| Geodeindex-like | $4.0M | 6.94% | +223.16% |
| Manager | Value | % base | |
|---|---|---|---|
| ARK | $10.3M | 17.84% | −1.02% |
| BlackRockindex-like | $10.3M | 17.77% | +375.73% |
| Vanguardindex-like | $8.5M | 14.72% | +566.87% |
| DRW Securities | $4.9M | 8.41% | new |
| Geodeindex-like | $4.0M | 6.94% | +223.16% |
Bull1
Bear2